Berislav V Zlokovic Selected Research

Low Density Lipoprotein Receptor-Related Protein-1 (LDL-Receptor Related Protein)

10/2012	Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.
9/2012	Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis.
1/2011	Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.
7/2008	New therapeutic targets in the neurovascular pathway in Alzheimer's disease.
9/2005	Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease.
11/2004	RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Berislav V Zlokovic Research Topics

Disease

40	Alzheimer Disease (Alzheimer's Disease) 12/2023 - 06/2002
23	Ischemic Stroke 01/2022 - 05/2003
23	Stroke (Strokes) 01/2022 - 03/2003
18	Cognitive Dysfunction 12/2023 - 11/2004
16	Dementia (Dementias) 12/2023 - 04/2007
15	Hemorrhage 12/2018 - 04/2003
8	Infarction (Infarctions) 01/2022 - 04/2003
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2013
8	Inflammation (Inflammations) 03/2021 - 05/2004
7	Amyloidosis 01/2013 - 06/2002
5	Ischemia 01/2022 - 06/2003
5	Sepsis (Septicemia) 01/2018 - 03/2006
5	Hypoxia (Hypoxemia) 01/2018 - 04/2003
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 04/2003
4	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2018 - 04/2008
3	Edema (Dropsy) 01/2022 - 04/2003
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020 - 11/2004
3	Brain Injuries (Brain Injury) 01/2019 - 04/2003
3	Neuroinflammatory Diseases 01/2019 - 11/2004
3	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2016 - 05/2012
3	Nervous System Diseases (Neurological Disorders) 01/2013 - 01/2009
3	Embolic Stroke 09/2012 - 09/2005
3	Brain Ischemia (Cerebral Ischemia) 11/2008 - 05/2004
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 03/2024 - 11/2006
2	Malaria 02/2023 - 01/2023
2	Migraine Disorders (Migraine) 01/2022 - 03/2021
2	Disease Progression 01/2020 - 11/2009
2	Multiple Sclerosis 01/2018 - 01/2016
2	Brain Diseases (Brain Disorder) 01/2018 - 04/2012
2	Thrombosis (Thrombus) 11/2016 - 04/2003
2	Down Syndrome (Down's Syndrome) 04/2013 - 05/2012
2	Cerebral Hemorrhage 04/2013 - 08/2010
2	Amyloid angiopathy 01/2013 - 06/2002
2	Amyloid Plaque 09/2012 - 08/2005
2	Purpura Fulminans 04/2012 - 04/2007
2	Venous Thrombosis (Deep-Vein Thrombosis) 04/2012 - 04/2007
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 02/2009 - 04/2007
1	Encephalitis (Encephalitis, Rasmussen) 12/2022
1	Ganglion Cysts (Ganglion) 01/2022
1	Cerebral Small Vessel Diseases 01/2022
1	Headache (Headaches) 03/2021
1	Pain (Aches) 03/2021
1	Demyelinating Diseases (Demyelinating Disease) 01/2021
1	Carotid Stenosis (Carotid Artery Stenosis) 01/2021
1	Gliosis 01/2020
1	Shock 01/2019

Drug/Important Bio-Agent (IBA)

28	Amyloid (Amyloid Fibrils)IBA 02/2023 - 12/2002
27	Protein CIBA 03/2024 - 05/2003
19	AnticoagulantsIBA 01/2020 - 05/2003
16	Amyloid beta-PeptidesIBA 01/2015 - 06/2002
14	Biomarkers (Surrogate Marker)IBA 12/2023 - 01/2011
13	Tissue Plasminogen Activator (Alteplase)FDA Link 03/2024 - 09/2005
10	Apolipoprotein E4IBA 11/2022 - 05/2012
10	Peptides (Polypeptides)IBA 01/2022 - 06/2002
10	Neuroprotective AgentsIBA 01/2022 - 04/2003
10	Proteins (Proteins, Gene)FDA Link 03/2021 - 05/2004
6	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 03/2003
6	Low Density Lipoprotein Receptor-Related Protein-1 (LDL-Receptor Related Protein)IBA 10/2012 - 11/2004
5	3K3A-APC proteinIBA 01/2022 - 12/2013
5	PAR-1 ReceptorIBA 12/2018 - 11/2006
5	Hemoglobins (Hemoglobin)IBA 08/2013 - 03/2009
4	Serine Proteases (Serine Protease)IBA 01/2019 - 12/2004
3	Cyclophilin AIBA 07/2021 - 01/2020
3	LDL Receptors (LDL Receptor)IBA 09/2012 - 08/2004
3	Protein SIBA 04/2012 - 04/2003
3	Endothelial Protein C ReceptorIBA 05/2004 - 03/2003
2	ArtesunateIBA 02/2023 - 01/2023
2	LipidsIBA 01/2023 - 04/2012
2	HDL LipoproteinsIBA 01/2023 - 04/2012
2	Contrast MediaIBA 01/2022 - 12/2019
2	GadoliniumIBA 01/2022 - 12/2019
2	Particulate MatterIBA 01/2021 - 01/2021
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2020 - 11/2006
2	ApolipoproteinsIBA 04/2013 - 09/2012
2	NeurotoxinsIBA 04/2013 - 04/2007
2	drotrecogin alfa activated (Xigris)FDA Link 01/2012 - 05/2009
2	Blood Proteins (Serum Proteins)IBA 11/2010 - 05/2004
2	Superoxide Dismutase-1IBA 11/2009 - 04/2008
2	Receptor for Advanced Glycation End ProductsIBA 07/2008 - 11/2004
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 12/2022
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 03/2021
1	Fibrinogen (Factor I)FDA Link 03/2021
1	AlbuminsIBA 03/2021
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2021
1	Eicosapentaenoic AcidIBA 09/2020
1	Docosahexaenoic AcidsIBA 09/2020
1	Retinaldehyde (Retinal)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	CytokinesIBA 01/2020
1	Tenecteplase FDA Link 01/2020
1	UbiquitinIBA 01/2019
1	TransducinIBA 01/2019
1	Cullin Proteins (Cullins)IBA 01/2019
1	pleiotrophin (HARP)IBA 01/2019
1	Tripartite Motif ProteinsIBA 01/2019

Therapy/Procedure

24	Therapeutics 02/2022 - 05/2004
3	Thrombectomy 01/2021 - 01/2018
3	Thrombolytic Therapy 02/2011 - 09/2005
1	Intravenous Infusions 01/2022